Cost –effectiveness of BTK inhibitors vs bendamustine and rituximab in chronic lymphocytic leukemia patients
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - December 7, 2023 Category: Cancer & Oncology Authors: Jing Nie Huina Wu Qian Wu Qi Liu Lihui Liu Jiyong Wu Source Type: research
Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study
This study performed a long-term economic evaluation of the first-line treatment strategi... (Source: BMC Health Services Research)
Source: BMC Health Services Research - December 5, 2023 Category: General Medicine Authors: Yuan Hong, Xichuang Chen, Yuanquan Hong, Xingfang Xiao, Yan Wang, Xiaohong You, Jingyi Mi, Tao Zhou, Panpan Zheng and Zhihu Huang Tags: Research Source Type: research
